N/A N=18 Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism
Cardiovascular Diseases
Primary: Percentage of Thrombus Obstruction — 33; 31; 23; 22 percentage of thrombus obstruction
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=22 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
Hypertension, Pulmonary · Altitude Sickness
Primary: Mean Pulmonary Artery Pressure — 16.8667; 15.6545; 16.3800; 16.6833 mm Hg
Phase 1 N=8 Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Safety — 0 participants
N/A N=100 CTEPH Identification an Standard Computerised Tomography Pulmonary Angiography in Pulmonary Embolism Patients
CTEPH · Pulmonary Embolism · Early Diagnosis
Primary: To Identify the Accuracy of Routine CTPA for the Distinction of CTEPH From Acute PE. — 70; 70 Sensitivity
Phase 3 N=30 Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
Congestive Heart Failure · Heart Failure, Left-Sided · Left-Sided Heart Failure
Primary: Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR) — -0.6; 0.1 wood units — p=0.003
N/A N=36 The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery
Lung Neoplasms
Primary: Discharge 2weeks Exercise Capacity — 408.61; 311.94 meter(M) — p=<0.05
Phase 3 N=5,395 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment — 0.0226; 0.0269 proportion…
Phase 3 N=350 Breath Analysis Technique to Diagnose Pulmonary Embolism
Pulmonary Embolism
Primary: Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement — 0; 136 percent change
Phase 3 N=4,833 Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
Pulmonary Embolism
Primary: Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal…
N/A N=120 Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism
Deep Vein Thrombosis · Pulmonary Embolism
Primary: Major Bleeding Complication — 0; 3 participants
N/A N=119 Evaluating the Safety and Efficacy of the Indigo® Aspiration System in Acute Pulmonary Embolism
Pulmonary Embolism
Primary: Right Ventricle/Left Ventricle (RV:LV) Ratio — 0.43 Change in RV/LV Diameter Ratio
Phase 4 N=114 A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
Pulmonary Embolism
Primary: Mean Duration of Hospitalization — 0.191; 1.393 Days — p=<.0001
Phase 3 N=2,482 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…
Phase 3 N=59 ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
Submassive Pulmonary Embolism
Primary: Reduction of RV/LV Ratio — 0.03; 0.30 Ratio
Phase 4 N=131 Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
Pulmonary Embolism and Thrombosis
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…